{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T14:05:40Z","timestamp":1789740340154,"version":"4.0.1"},"reference-count":27,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"unspecified","delay-in-days":17,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005423","name":"Akademiska Sjukhuset","doi-asserted-by":"publisher","award":["Not applicable"],"award-info":[{"award-number":["Not applicable"]}],"id":[{"id":"10.13039\/501100005423","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2026,8,26]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study aimed to assess cardiovascular (CV) risk across the full spectrum of dysglycaemia levels following myocardial infarction (MI).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective registry-based cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>All patients with MI in Sweden registered in the cardiac rehabilitation registry within the Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) between 2006 and 2017.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>In total, 47\u2009558 patients over the age of 18 attending cardiac rehabilitation post-MI, with available information on glycaemic levels.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary outcome was major adverse CV events (MACE), a composite of all-cause mortality, MI and ischaemic stroke until the end of follow-up (30 June 2018). Secondary outcomes included all the components of MACE, CV mortality and hospitalisation for heart failure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pre-diabetes and possible diabetes were present in 20.6%, new-onset diabetes in 3.2% and known diabetes in 21.1%. During a median follow-up of 4.7 years, 9321 patients experienced MACE. A stepwise increase across glycaemic categories was observed, with HRs of 1.07 (95% CI 1.00 to 1.14) for pre-diabetes, 1.22 (95% CI 1.11 to 1.34) for possible diabetes, 1.22 (95% CI 1.08 to 1.37) for new-onset diabetes and 1.73 (95% CI 1.64 to 1.82) for known diabetes, compared with normoglycaemia. A near-linear association between fasting glucose and outcomes was observed across all patients, while glycated haemoglobin appears predictive mainly in those with established diabetes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Glycaemic disturbances early after MI, including hyperglycaemia below the diagnostic threshold for diabetes, are associated with a progressively higher risk of adverse outcomes. Beyond routine screening, these findings support close follow-up of at-risk patients, irrespective of diabetes status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2026-121970","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:31:05Z","timestamp":1789738265000},"page":"e121970","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Diabetes status, fasting glucose and HbA1c, and outcomes after myocardial infarction: a retrospective registry-based Swedish cohort study"],"prefix":"10.1136","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-2098-8833","authenticated-orcid":false,"given":"Azzum","family":"Haider","sequence":"first","affiliation":[{"name":"Uppsala Universitet, Uppsala, Sweden"},{"name":"Cardiology, V\u00e4ster\u00e5s Central Hospital, V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emil","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Divan","family":"Ishak","sequence":"additional","affiliation":[{"name":"Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9368-6325","authenticated-orcid":false,"given":"Nermin","family":"Hadziosmanovic","sequence":"additional","affiliation":[{"name":"Department of Medical Sciences, Cardiology, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Norhammar","sequence":"additional","affiliation":[{"name":"Karolinska Institutet, Stockholm, Sweden"},{"name":"Capio Sankt G\u00f6rans Sjukhus, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-9659-6959","authenticated-orcid":false,"given":"Matthijs","family":"Velders","sequence":"additional","affiliation":[{"name":"Department of Clinical Physiology, V\u00e4ster\u00e5s Hospital, V\u00e4ster\u00e5s, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2480-9547","authenticated-orcid":false,"given":"Gorav","family":"Batra","sequence":"additional","affiliation":[{"name":"Uppsala Universitet, Uppsala, Sweden"},{"name":"Uppsala Clinical Research Centre, Uppsala University, Uppsala, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"2026091806301900000_16.9.e121970.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2021.109119"},{"key":"2026091806301900000_16.9.e121970.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.037885"},{"key":"2026091806301900000_16.9.e121970.3","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-018-0728-6","article-title":"Prevalence of cardiovascular disease in type 2 diabetes: a systematic literature review of scientific evidence from across the world in 2007-2017","volume":"17","author":"Einarson","year":"2018","journal-title":"Cardiovasc Diabetol"},{"key":"2026091806301900000_16.9.e121970.4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60576-4"},{"key":"2026091806301900000_16.9.e121970.5","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-011-2404-1"},{"key":"2026091806301900000_16.9.e121970.6","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1001\/jamacardio.2020.4511","article-title":"Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis","volume":"6","author":"McGuire","year":"2021","journal-title":"JAMA Cardiol"},{"key":"2026091806301900000_16.9.e121970.7","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026091806301900000_16.9.e121970.8","doi-asserted-by":"crossref","DOI":"10.1186\/s12933-015-0296-y","article-title":"Patients with coronary artery disease and diabetes need improved management: a report from the EUROASPIRE IV survey: a registry from the EuroObservational Research Programme of the European Society of Cardiology","volume":"14","author":"Gyberg","year":"2015","journal-title":"Cardiovasc Diabetol"},{"key":"2026091806301900000_16.9.e121970.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60484-9"},{"key":"2026091806301900000_16.9.e121970.10","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ahj.2025.04.028","article-title":"Data quality assessment in the SWEDEHEART registry: Insights from serial audits on completeness and accuracy","volume":"288","author":"Leosdottir","year":"2025","journal-title":"Am Heart J"},{"key":"2026091806301900000_16.9.e121970.11","unstructured":"Classification of diabetes mellitus 2019. Geneva, Switzerland World Health Organization; 2019."},{"key":"2026091806301900000_16.9.e121970.12","doi-asserted-by":"publisher","DOI":"10.1177\/096228029900800102"},{"key":"2026091806301900000_16.9.e121970.13","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61969-3"},{"key":"2026091806301900000_16.9.e121970.14","doi-asserted-by":"crossref","first-page":"108959","DOI":"10.1016\/j.diabres.2021.108959","article-title":"Does a strict glycemic control during acute coronary syndrome play a cardioprotective effect? Pathophysiology and clinical evidence","volume":"178","author":"Caturano","year":"2021","journal-title":"Diabetes Res Clin Pract"},{"key":"2026091806301900000_16.9.e121970.15","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht149"},{"key":"2026091806301900000_16.9.e121970.16","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht142"},{"key":"2026091806301900000_16.9.e121970.17","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.188629"},{"key":"2026091806301900000_16.9.e121970.18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.063374"},{"key":"2026091806301900000_16.9.e121970.19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022190"},{"key":"2026091806301900000_16.9.e121970.20","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/ejhf.3184","article-title":"Dapagliflozin in patients with heart failure and previous myocardial infarction: A participant-level pooled analysis of DAPA-HF and DELIVER","volume":"26","author":"Peikert","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"2026091806301900000_16.9.e121970.21","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad192"},{"key":"2026091806301900000_16.9.e121970.22","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10132876","article-title":"Management of High-Risk Atherosclerotic Patients by Statins May Be Supported by Logistic Model of Intima-Media Thickening","volume":"10","author":"Formanowicz","year":"2021","journal-title":"J Clin Med"},{"key":"2026091806301900000_16.9.e121970.23","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.8.1879"},{"key":"2026091806301900000_16.9.e121970.24","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1979.03290450033020"},{"key":"2026091806301900000_16.9.e121970.25","doi-asserted-by":"publisher","DOI":"10.2337\/dc10-0286"},{"key":"2026091806301900000_16.9.e121970.26","doi-asserted-by":"publisher","DOI":"10.1007\/s00125-012-2579-0"},{"key":"2026091806301900000_16.9.e121970.27","doi-asserted-by":"publisher","DOI":"10.2337\/dc19-0018"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2026-121970","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T13:31:07Z","timestamp":1789738267000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2026-121970"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":27,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,18]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjopen-2026-121970"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2026-121970","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}